Dash Bio
PrivateLast Round
Series A
Jul 14, 2026
Est. Valuation
$17.5M
Total Funding Raised
$17.5M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Dash Bio is a biotechnology company that provides an automated bioanalysis platform using AI and robotics to accelerate clinical drug development for pharmaceutical and biotech companies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Vertical SaaS, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dash Bio Comparables
Compare Dash Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Phylo | 82% | |
| Benchling | 77% | |
| TeselaGen Biotechnology | 77% |
Dash Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 14, 2026 | ||||
| Early Funding | Jul 23, 2025 | ||||
| Seed | Oct 24, 2024 |
Dash Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cybernetix Ventures | Early Funding |
| LifeX Ventures | Seed, Early Funding |
| LifeX Global | Early Funding |
| Oak HC/FT | Series A |
| LifeX Ventures | Seed, Early Funding |
| The Aligned Fund | Early Funding |
| Freestyle Ventures | Early Funding, Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2026
Grew 25% QoQ, from 36 to 45 employees.
- Sep 21, 2026
Open roles increased to 22, doubling the trailing average.
Recent news
Latest coverage and updates
- recognized_asOct 14, 2026
dash.bio is named to Greenfield Partners’ AI Disruptors 60 Class of 2026, an annual selection of 60 groundbreaking AI startups unveiled at TechCrunch Disrupt 2026 in California on Oct 14th '26.
- receives_financingAug 3, 2026
In Aug '26, dash.bio raises a $30M Series A led by Oak HC/FT, with participation from Freestyle Capital and Swift Ventures, to accelerate drug development timelines.
Dash Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Dash Bio's valuation, stock price, and market status.
Is Dash Bio a public or private company?
Dash Bio is a private company.
What is the current stock price of Dash Bio?
Dash Bio is a private company, so its shares have no public market price. Caplight tracks Dash Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dash Bio worth (valuation)?
Dash Bio's valuation is estimated at $17.5M based on funding round data.
Can I buy Dash Bio stock?
Dash Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dash Bio's last funding round?
Dash Bio's most recent funding round was Series A on July 14, 2026.
Who are the main investors in Dash Bio?
Key investors in Dash Bio include Oak HC/FT, The Aligned Fund, Freestyle Ventures.
Will Dash Bio IPO soon?
No public IPO plans have been announced for Dash Bio.
How can I track Dash Bio secondary market activity?
Caplight tracks bids, offers, and trades in Dash Bio's shares on secondary markets.